Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
Author:
Funder
Timcc
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
http://link.springer.com/content/pdf/10.1007/s00262-016-1909-3.pdf
Reference49 articles.
1. Ascierto PA (2015) Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. Cancer Immunol Immunother 64:271–274. doi: 10.1007/s00262-014-1647-3
2. Hammerich L, Binder A, Brody JD (2015) In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 9:1966–1981. doi: 10.1016/j.molonc.2015.10.016
3. Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE (2015) In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccin Immunother 11:1901–1909. doi: 10.1080/21645515.2015.1049779
4. Wong KK, Li WA, Mooney DJ, Dranoff G (2016) Advances in therapeutic cancer vaccines. Adv Immunol 130:191–249. doi: 10.1016/bs.ai.2015.12.001
5. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695–1710. doi: 10.1084/jem.20130579
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses;Nature Communications;2024-09-03
2. Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity;Journal for ImmunoTherapy of Cancer;2024-01
3. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook;Pharmaceutics;2023-06-23
4. CarboCell combinatorial immunotherapy orchestrates curative anticancer immune activation of the tumor microenvironment;2023-02-03
5. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors;Journal for ImmunoTherapy of Cancer;2022-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3